REMARKS

Claims 2-10, and 21-25 are canceled without prejudice. Claims 26-39 are newly presented for examination. Applicants have elected Group VI for examination as required with the above-presented traverse.

Amendments to the Claims

The amendments to the claims add no new matter. Support for the new claims is provided throughout the specification and as exemplified by the table below.

Claim	Subject matter of claim	Support in Specification
26	wherein said immunogen is an attenuated form of human immunodeficiency virus	Original claim 2, see p. 6, line 13
27	wherein said immunogen has been attenuated by removing all or part of the nef gene from the nucleic acid of said human immunodeficiency virus	Original claim 3, see p. 6, 2nd full paragraph
28	wherein said immunogen is a subunit of said human immunodeficiency virus	Original claim 4, see p. 6, first paragraph
29	wherein said immunogen is a gp120 subunit of said human immunodeficiency virus	Original claim 5, see paragraph bridging pages 8 and 9
30	wherein said immunogen is a gp160 subunit of said human immunodeficiency virus	Original claim 6, see paragraph bridging pages 8 and 9
31	wherein said immunogen is an inactivated human immunodeficiency virus	Original claim 7, p.6, line 5
32	wherein said immunogen has been inactivated by removing a sufficient portion of its genetic material so as to render it incapable of replicating	Original claim 8, see page 10, first full paragraph
33	wherein the genetic material removed from said human immunodeficiency virus is a portion of a gene coding for a gag nucleocapsid protein	Original claim 9, Ex ample 4
34	wherein said human immunodeficiency virus has been inactivated by exposure to a solution of betapropiolactone	Original claim 10, see p. 9, last line

Claim	Subject matter of claim	Support in Specification
35	wherein said immunogen is an infectious form of human immunodeficiency virus administered in a subinfectious amount	Original claim 11, page 11, first full paragraph
36	cell mediated response is determined to be present using a T-Cell proliferation assay if the uptake of thymidine by antigen-stimulated cells is at least four-fold above background	Original claim 15, see p. 17, middle paragraph
37	wherein a cell mediated response is determined to be present using an IL-2 assay if the production of IL-2 by antigen-stimulated cells is at least four-fold above background	Original claim 16, see paragraph bridging pp. 17 and 18

Support for the subject matter of new independent claims 38 and 39 is found in claim 17 and as indicated for claims 26-37 above and throughout the specification as filed.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,

Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP (925) 472-5012
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415)576-0200
Fax: (415) 576-0300
FJM:mmm
WC 9045968 v1